X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (22333) 22333
Patent (60) 60
Book Chapter (35) 35
Magazine Article (7) 7
Dissertation (3) 3
Conference Proceeding (1) 1
Publication (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
open-label (20807) 20807
humans (13397) 13397
oncology (8181) 8181
female (6181) 6181
male (5628) 5628
double-blind (4675) 4675
chemotherapy (4659) 4659
middle aged (4376) 4376
treatment outcome (3842) 3842
adult (3827) 3827
pharmacology & pharmacy (3609) 3609
aged (3574) 3574
cancer (3434) 3434
multicenter (3187) 3187
care and treatment (2942) 2942
efficacy (2485) 2485
1st-line treatment (2477) 2477
clinical trials (2450) 2450
safety (2219) 2219
therapy (2216) 2216
patients (2167) 2167
drug therapy (2077) 2077
immunotherapy (2017) 2017
mutation (1981) 1981
analysis (1947) 1947
survival (1869) 1869
metastasis (1742) 1742
research (1718) 1718
medicine & public health (1653) 1653
antineoplastic agents - therapeutic use (1647) 1647
psychiatry (1645) 1645
trial (1641) 1641
aged, 80 and over (1552) 1552
antineoplastic combined chemotherapy protocols - therapeutic use (1533) 1533
review (1533) 1533
hematology (1499) 1499
animals (1474) 1474
clinical neurology (1458) 1458
lung cancer (1452) 1452
cancer therapies (1382) 1382
health aspects (1370) 1370
medicine, general & internal (1361) 1361
tumors (1319) 1319
lung neoplasms - drug therapy (1247) 1247
adolescent (1235) 1235
prognosis (1235) 1235
cell lung-cancer (1157) 1157
surgery (1155) 1155
medical research (1154) 1154
randomized controlled trials as topic (1131) 1131
gefitinib (1119) 1119
retrospective studies (1100) 1100
melanoma (1082) 1082
carcinoma, non-small-cell lung - drug therapy (1077) 1077
young adult (1075) 1075
erlotinib (1047) 1047
phase-iii (1044) 1044
phase-ii (1024) 1024
docetaxel (1016) 1016
studies (1009) 1009
nivolumab (1007) 1007
disease-free survival (1002) 1002
abridged index medicus (987) 987
immunology (981) 981
respiratory system (967) 967
phase-iii trial (953) 953
placebo-controlled trial (947) 947
medicine, research & experimental (936) 936
risk factors (930) 930
protein kinase inhibitors - therapeutic use (912) 912
neurosciences (910) 910
child (885) 885
clinical trials as topic (885) 885
usage (885) 885
adenocarcinoma (861) 861
lung cancer, non-small cell (860) 860
open-label trial (858) 858
drug therapy, combination (839) 839
quality-of-life (839) 839
pembrolizumab (838) 838
lung neoplasms - genetics (836) 836
breast cancer (824) 824
internal medicine (823) 823
non-small cell lung cancer (821) 821
targeted therapy (820) 820
phase-ii trial (816) 816
dosage and administration (810) 810
combination (805) 805
epidermal growth factor (804) 804
children (794) 794
management (790) 790
quality of life (789) 789
endocrinology & metabolism (785) 785
pharmacokinetics (782) 782
medicine, experimental (773) 773
molecular targeted therapy (762) 762
neoplasm staging (761) 761
randomized controlled-trial (761) 761
bevacizumab (757) 757
lung neoplasms - pathology (748) 748
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21690) 21690
German (348) 348
French (205) 205
Spanish (103) 103
Chinese (59) 59
Japanese (38) 38
Portuguese (18) 18
Hungarian (17) 17
Italian (15) 15
Turkish (15) 15
Polish (13) 13
Russian (12) 12
Korean (7) 7
Czech (6) 6
Slovenian (3) 3
Icelandic (2) 2
Dutch (1) 1
Esperanto (1) 1
Georgian (1) 1
Slovak (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neurosurgery, ISSN 1524-4040, 2019, Volume 84, Issue 3, pp. E134 - E135
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 28, pp. 2836 - 2844
PurposeMetastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival... 
GASTROESOPHAGEAL | OPEN-LABEL | SOLID TUMORS | ONCOLOGY | BLOCKADE | PD-1 | ORIGINAL REPORTS
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 1, pp. 61 - 67
Purpose The anti-programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multicohort, phase IB study of patients with programmed death... 
LIGAND-1 | MULTICENTER | ONCOLOGY | PATHWAY | SQUAMOUS-CELL CARCINOMA | OPEN-LABEL | PD-1 | EXPRESSION | CANCER | CD8(+) T-CELLS
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 12/2017, Volume 318, Issue 23, pp. 2306 - 2316
Journal Article
Neurology, ISSN 0028-3878, 07/2018, Volume 91, Issue 4, pp. e364 - e373
OBJECTIVETo evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for... 
CONTROLLED-TRIAL | DICLOFENAC POTASSIUM | TRIPTANS SEROTONIN | EFFICACY | HEADACHE | 5-HT1B/1D AGONISTS | TOLERABILITY | DOUBLE-BLIND | OPEN-LABEL | PREVENTION AMPP | CLINICAL NEUROLOGY | 101 | 321 | 222 | 302
Journal Article
Blood, ISSN 1528-0020, 2018, Volume 131, Issue 17, pp. 1910 - 1919
Our 5-year experience shows sustained single-agent efficacy of ibrutinib in CLL patients, with complete response rates increasing over time. Long-term... 
BENDAMUSTINE | MULTICENTER | FLUDARABINE PLUS CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | RITUXIMAB | INITIAL THERAPY | OPEN-LABEL | CLL8 TRIAL | HEMATOLOGY | CHLORAMBUCIL | PREVIOUSLY UNTREATED PATIENTS | Clinical Trials and Observations
Journal Article
Blood, ISSN 1528-0020, 2018, Volume 131, Issue 15, pp. 1704 - 1711
ORR was 67% with venetoclax for 36 patients with CLL refractory to or who relapsed after idelalisib; median PFS has not yet been reached. Common adverse events... 
CLL | OPEN-LABEL | INHIBITOR | HEMATOLOGY | Clinical Trials And Observations
Journal Article
JAMA Dermatology, ISSN 2168-6068, 10/2015, Volume 151, Issue 10, pp. 1103 - 1109
IMPORTANCE The cutaneous adverse effects of the BRAF inhibitors vemurafenib and dabrafenib mesylate in the treatment of metastatic melanoma have been well... 
DABRAFENIB | METASTATIC MELANOMA | MULTICENTER | THERAPY | KERATOSIS | ERUPTION | IMPROVED SURVIVAL | RAF INHIBITORS | OPEN-LABEL | VEMURAFENIB | DERMATOLOGY
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 19, pp. 1973 - 1980
PurposeVenetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients... 
MULTICENTER | OPEN-LABEL | ONCOLOGY | BCL-2 INHIBITOR
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2008, Volume 26, Issue 35, pp. 5705 - 5712
Journal Article
Blood, ISSN 1528-0020, 2018, Volume 132, Issue 15, pp. 1568 - 1572
Cytoreduction with obinutuzumab and ibrutinib followed by the addition of venetoclax has acceptable safety with no tumor lysis syndrome. This combination has... 
ANTIBODIES | OPEN-LABEL | THERAPY | HEMATOLOGY | FLUDARABINE | RITUXIMAB | 8 | 12 | Clinical Trials and Observations | 39
Journal Article
The Oncologist, ISSN 1083-7159, 02/2020, Volume 25, Issue 2, pp. 121 - e213
Lessons Learned HyperAcute Renal immunotherapy was well tolerated and demonstrated antitumor activity in patients requiring salvage‐line treatment for... 
MELANOMA | EVEROLIMUS | ONCOLOGY | OPEN-LABEL | COMBINATION | NIVOLUMAB | CANCER
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 3, pp. 233 - 245
Journal Article